STAAR Surgical (NASDAQ:STAA) Stock Rating Lowered by William Blair

STAAR Surgical (NASDAQ:STAA) was downgraded by stock analysts at William Blair from an “outperform” rating to a “market perform” rating in a research report issued on Wednesday, MarketBeat Ratings reports.

Several other research firms have also commented on STAA. Stephens raised shares of STAAR Surgical to a “hold” rating in a research report on Monday, December 2nd. Canaccord Genuity Group decreased their target price on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a research report on Monday, December 9th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a report on Tuesday, January 7th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $26.86.

STAAR Surgical Trading Down 3.2 %

STAA opened at $15.96 on Wednesday. The firm has a market cap of $786.51 million, a price-to-earnings ratio of 36.27 and a beta of 0.62. STAAR Surgical has a 12 month low of $13.50 and a 12 month high of $52.68. The stock has a fifty day moving average price of $23.57 and a 200-day moving average price of $29.15.

Insider Transactions at STAAR Surgical

In other news, major shareholder Broadwood Partners, L.P. bought 53,500 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were purchased at an average price of $24.24 per share, for a total transaction of $1,296,840.00. Following the completion of the transaction, the insider now directly owns 10,821,931 shares in the company, valued at approximately $262,323,607.44. This represents a 0.50 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders purchased 105,876 shares of company stock worth $2,487,168. Company insiders own 1.00% of the company’s stock.

Institutional Trading of STAAR Surgical

Several large investors have recently made changes to their positions in STAA. Vanguard Group Inc. lifted its position in STAAR Surgical by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock valued at $142,232,000 after purchasing an additional 319,441 shares during the period. State Street Corp lifted its holdings in shares of STAAR Surgical by 0.5% in the 3rd quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier’s stock valued at $72,092,000 after buying an additional 10,430 shares during the period. Resona Asset Management Co. Ltd. purchased a new stake in shares of STAAR Surgical in the fourth quarter worth about $36,411,000. Geode Capital Management LLC grew its holdings in STAAR Surgical by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock worth $43,641,000 after acquiring an additional 31,212 shares during the period. Finally, Yunqi Capital Ltd raised its position in STAAR Surgical by 48.9% during the fourth quarter. Yunqi Capital Ltd now owns 767,413 shares of the medical instruments supplier’s stock valued at $18,640,000 after acquiring an additional 252,113 shares in the last quarter. 96.70% of the stock is owned by hedge funds and other institutional investors.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.